GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Alcidion Group ALC.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.11

0.00%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Alcidion Group

Its shares trade on ASX under the ticker ALC.AX. It has been listed since 24 June 2011. In the fiscal year to 30 June 2026, it reported revenue of A$51.6m and net income of A$2.3m. At that date it held total assets of A$121.9m and shareholders' equity of A$90.9m.

Alcidion Group Ltd. engages in the development and provision of healthcare software products marketed under the Miya, Patientrack, Smartpage and ExtraMed brands. The company is headquartered in Melbourne, Victoria. The company went IPO on 2011-06-24. Its principal activities include the development and licensing of its own healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and PAS), the reselling of selected healthcare software products from its strategic partners and the delivery of product implementation, product support and maintenance, systems integration, and data analysis services to healthcare customers in Australia, New Zealand, and the United Kingdom. Its flagship product, Miya Precision, is a smart clinical solution based on a FHIR-event platform that facilitates multiple clinical and operational applications. Its other products include Smartpage, Patientrack, and Silverlink PCS. Smartpage is an advanced smartphone and Web-based system for hospital communication and task management, addressing the requirements of both clinical and non-clinical users. The firm services over 400 hospitals.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Technology
Listed since
24 Jun 2011

Leadership

Pay as last reported

  • Ms. Rebecca WilsonNon-Executive Independent Chairman of the BoardA$105,833
  • Ms. Kate QuirkeChief Executive Officer, Managing Director, Executive Director, since 2018A$610,625
  • Mr. Matthew GeppChief Financial OfficerA$320,956
  • Mr. Paul DefleyChief Medical Officer. Managing Director, UK
  • Mr. Michael SapountzisCompany Secretary
  • Mr. William SmartNon-Executive Director
  • Prof. Andrew WayNon-Executive Director
  • Mr. Daniel SharpNon-Executive Independent DirectorA$62,500

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Miya Precision is a smart clinical solution based on a FHIR-event platform for multiple applications.
  • Alcidion serves over 400 hospitals across Australia, New Zealand, and the United Kingdom.
  • The company develops and licenses its own healthcare software products including Miya Observations and Flow modules.

Weaknesses

  • Alcidion's business relies on healthcare software products without mentioning specific competitors or market share.
  • The company's operations are limited to Australia, New Zealand, and the United Kingdom with no global expansion mentioned.
  • Alcidion's product portfolio includes Smartpage and Patientrack but lacks details on market penetration.

Opportunities

  • Expanding into new markets beyond Australia, New Zealand, and the United Kingdom could increase revenue.
  • The growing demand for healthcare software solutions presents a significant opportunity for Alcidion.
  • Alcidion can leverage its Miya Precision platform to develop new applications for the Health Care sector.

Threats

  • The healthcare software market faces increasing competition from other providers without specific names mentioned.
  • Regulatory changes in the Health Care sector could impact Alcidion's operations without specific laws cited.
  • Economic downturns in Australia, New Zealand, and the United Kingdom may reduce healthcare spending.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.